Credit rating agency, Credit Analysis and Research (CARE) has reaffirmed Wockhardt’s rating for total Working Capital limit as ‘AA’ and ‘A1+’ for Long - Term Bank Facilities (Fund Based) and Short Term Bank Facilities (Non Fund Based) respectively.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
